文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

葡萄牙临床沙眼衣原体菌株耐药遗传标记与基因组背景的多重NGS调查

Surveying genetic markers of antibiotic resistance and genomic background in Chlamydia trachomatis: insights from a multiplex NGS-based approach in clinical strains from Portugal.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

研究对葡萄牙国家性传播感染参考实验室收藏的502份沙眼衣原体阳性样本(多为肛门直肠渗出物)进行5个靶点的PCR与测序,涵盖可能驱动耐药的大环内酯类与氟喹诺酮类相关位点及基因组背景分型位点。结果未发现与耐药明确相关的23S rRNA突变,3份样本携带GyrA Ser83Ile突变;pmpH、CT105上游及CT442区域可区分LGV/非LGV及L2/L2b背景,CT105上游插入序列对LGV具有完全特异性。

要点

  • 502份沙眼衣原体阳性样本中未检出与耐药明确相关的23S rRNA突变。
  • 3份样本携带GyrA Ser83Ile突变,其中2份为重组L2-L2b/D-Da,1份为L2。
  • CT105上游插入序列对LGV完全特异,有望用于快速LGV诊断。

核心结论

  • 研究提示已知的耐药遗传决定因素在临床沙眼衣原体菌株中并未播散,所建立的探索性方法适用于LGV/非LGV及L2/L2b基因组背景区分。

研究设计与样本

  • 研究对葡萄牙国家性传播感染参考实验室收藏的502份沙眼衣原体阳性样本(多为肛门直肠渗出物)进行5个靶点的PCR与测序。
  • 靶点包括可能驱动耐药的23S rRNA、gyrA、parC位点,以及pmpH的9 bp插入、CT105上游74 bp插入和CT442多态性。
  • 采用多重PCR偶联NGS的探索性方法,用于获取菌株基因组骨架的补充信息。

主要发现

  • 无样本检出与耐药明确相关的23S rRNA突变。
  • 3份样本携带GyrA Ser83Ile突变:2份为重组L2-L2b/D-Da(0.4%),1份为L2(0.2%)。
  • pmpH、CT105上游及CT442筛查区域与LGV/非LGV区分完全一致。
  • pmpH的L2b特异性遗传位点见于全部L2b及重组L2-L2b/D-Da ompA基因型,也见于96.0%的L2样本,后者可能同样具有L2b基因组骨架。
  • CT105上游插入序列对LGV具有完全特异性,是开发快速LGV诊断检测的有前景靶点。

关键数值与推荐

  • GyrA Ser83Ile突变见于3份样本:重组L2-L2b/D-Da 2份(0.4%)与L2 1份(0.2%)。
  • pmpH的L2b特异性位点在L2b及重组L2-L2b/D-Da ompA基因型中全部检出,在L2样本中检出率为96.0%。
  • CT105上游插入序列对LGV具有完全特异性。

临床怎么用

  • 作者认为本研究增进了对沙眼衣原体分子流行病学的认识,提示已知耐药遗传决定因素未在临床菌株中播散。
  • 作者提出该探索性方法适用于LGV/非LGV及L2/L2b基因组背景区分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To survey genetic markers of potential antimicrobial resistance (AMR) to macrolides and fluoroquinolones among Chlamydia trachomatis-positive samples from the collection of the Portuguese National Reference Laboratory for Sexually Transmitted Infections (STIs), and explore a multiplex PCR approach coupled with NGS to provide complementary information regarding a strain's genomic backbone. METHODS: A total of 502 C. trachomatis-positive samples, mostly anorectal exudates, were subjected to PCR and sequencing of five targets, including loci potentially driving AMR (23S rRNA, gyrA and parC) and loci potentially informative about a strain's genomic backbone with emphasis on differentiation of lymphogranuloma venereum (LGV)/non-LGV and L2/L2b (a 9 bp insertion in pmpH, a 74 bp insertion upstream from CT105 and the polymorphic CT442). RESULTS: No samples evidenced 23S rRNA mutations recognizably linked to macrolide resistance. Three samples harboured the Ser83Ile mutation in GyrA putatively driving fluoroquinolone resistance: two recombinant L2-L2b/D-Da (0.4%) and one L2 (0.2%). The screened regions in pmpH, upstream CT105 and CT442 were fully concordant with LGV/non-LGV differentiation. As expected, the pmpH L2b-specific genetic trait locus was detected in all L2b and recombinant L2-L2b/D-Da ompA genotypes, but also in 96.0% of L2 specimens, which also likely possess an L2b genomic backbone. The insertion upstream from CT105 exhibited full LGV specificity, constituting a promising target for the development of rapid LGV diagnostic assays. CONCLUSIONS: This study contributes to enhancing the knowledge of C. trachomatis molecular epidemiology, suggesting that the known genetic determinants of AMR are not disseminated in clinical C. trachomatis strains, and presents an exploratory approach that can be suitable for LGV/non-LGV and L2/L2b genomic background differentiation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lodhia Z, Costa Da Silva J, Correia C, et al. Surveying genetic markers of antibiotic resistance and genomic background in Chlamydia trachomatis: insights from a multiplex NGS-based approach in clinical strains from Portugal. J Antimicrob Chemother. 2025. PMID: 39960073. doi:10.1093/jac/dkaf036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。